DAPT with aspirin (300/75–100 mg) and clopidogrel (300–600/75 mg) is recommended in this subset [72], whereas newer P2Y12 antagonists such as ticagrelor and prasugrel should be avoided considering the high bleeding risk and lacking data on effectiveness and safety in cancer patients [5]. This evidence concerns the gene P2RY12 and cancer.